/PRNewswire/ MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first.
Trulieve Announces the Opening of its Northampton Store
News provided by
Share this article
Share this article
Northampton location brings Trulieve s premium cannabis products and trusted customer experience to Massachusetts patients and customers
HOLYOKE, Mass., May 26, 2021 /PRNewswire/ -
Trulieve Cannabis Corp. ( Trulieve or The Company ) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States, today announced that the Massachusetts Cannabis Control Commission has approved the launch of Trulieve s operations in the Commonwealth of Massachusetts. Trulieve plans to open its first dispensary in the state on Thursday, June 3. To welcome the newest dispensary to Massachusetts, Northampton Mayor David Narkewicz will be in attendance for a ribbon cutting ceremony at 3:00 p.m.
/PRNewswire/ Pangaea Logistics Solutions Ltd. ("Pangaea" or the "Company") (NASDAQ: PANL), a global provider of comprehensive maritime logistics solutions,.
Medivir to present at the ABGSC Life Science Summit
News provided by
Share this article
STOCKHOLM, May 25, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, May 25.
The company will be represented by
Magnus Christensen, interim CEO, and Fredrik Öberg, Chief Scientific Officer.
The presentation will be available after the seminar on Medivirs website; www.medivir.com.
For additional information, please contact
Magnus Christensen, interim CEO and CFO
Telephone: +46 8 5468 3100
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat li